Feng Zhou | Oncology | Best Researcher Award

Dr. Feng Zhou, Fudan University, China.

Feng Zhou, Ph.D., is a seasoned pharmaceutical leader with over 15 years of experience in drug discovery and development. He has successfully contributed to the development of small molecules and biologics, particularly in oncology, immunology, and autoimmune diseases. His leadership has led to the advancement of numerous drugs, with several reaching clinical trials and market approval. Currently serving as Senior Director at Simcere Zaiming, Shanghai, Feng Zhou excels in building and managing teams, driving innovative research, and collaborating with academic and industrial partners. 👨‍🔬

Publication profile

Orcid

Education and Experience ()

Education

Ph.D. in Biochemistry & Molecular Biology, Fudan University, 2008
M.Sc. in Zoology, Yunnan University, 2005
B.Sc. in Biotechnology, Sichuan University, 2001

Experience

Senior Director, Head of In Vitro Pharmacology Platform, Simcere Zaiming, 2023-present
Senior Director, Head of In Vitro Pharmacology Platform, Simcere Pharma, 2019-2022
Deputy Director, In Vitro Pharmacology, Hutchison MediPharma, 2008-2019

Suitability for Best Researcher Award:

Dr. Feng Zhou, a highly accomplished researcher with over 15 years of experience in drug development, exemplifies the qualities of a leading candidate for the Best Researcher Award. His extensive expertise spans a broad spectrum of pharmaceutical innovations, from small molecules to biotherapeutics, underpinned by a robust track record of successful drug approvals and ongoing clinical trials.

Professional Development ()

Feng Zhou has a proven track record in preclinical drug development, with expertise spanning oncology, immunology, and autoimmune diseases. He has led multiple cross-functional teams and managed various clinical and near-clinical projects, including small molecules and biologics like T-cell engagers and antibody-drug conjugates. His contributions include establishing in vitro pharmacology platforms, leading biomarker identification studies, and overseeing external collaborations with CROs and academic institutions. With a strong focus on leveraging cutting-edge technologies, he has been instrumental in identifying biomarkers, advancing drug candidates, and supporting clinical trial designs.

Research Focus

Feng Zhou’s research primarily focuses on cancer biology, immuno-oncology, and autoimmune diseases. He has contributed to the development of small molecules, PROTACs, antibody-drug conjugates (ADCs), and T-cell engagers (TCEs). His expertise lies in translating preclinical findings into clinical strategies, where he has successfully driven biomarker identification and drug efficacy studies. His extensive knowledge of tumor biology and immune mechanisms allows him to design innovative therapeutic strategies, making significant contributions to both oncology and immunology fields.

Awards and Honors ()

Jiangsu Province Double Innovation Talent, 2020
Zijinshan Talent Pioneer Program, Nanjing, 2021
Industry Professor, China Pharmaceutical University, 2022

Publication Top Notes

SCR‐7952, a highly selective MAT2A inhibitor (2024) – MedComm | Cited by: Not yet available
Structure-based development and preclinical evaluation of SARS-CoV-2 3C-like protease inhibitor simnotrelvir (2023) – Nature Communications | Cited by: Not yet available
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD) (2023) – Breast Cancer Research | Cited by: Not yet available
Volitinib, a potent and highly selective c-Met inhibitor (2015) – Molecular Oncology | Cited by: 355
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) (2014) – Journal of Medicinal Chemistry | Cited by: 147
Post-transcriptional and post-translational regulation of PTEN by TGF-β1 (2009) – Journal of Cellular Biochemistry | Cited by: 52

Conclusion

Dr. Feng Zhou’s remarkable contributions to drug development, his strategic leadership in innovative research, and his collaborative spirit make him an outstanding candidate for the Best Researcher Award. His achievements not only highlight his individual excellence but also significantly contribute to the advancement of therapeutic strategies in the biomedical field, paving the way for future breakthroughs in medicine. Awarding him this recognition would not only honor his past accomplishments but also encourage further advancements in drug discovery and development.